

IFW



Attorney Docket No.: 38005-0194

Application No.: 10/820,703

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Lothar SCHWINK et al.

Application No.: 10/820,703

Filed: April 9, 2004

Group Art Unit: Unassigned

Examiner: Unassigned

For: AMINOALKYL-SUBSTITUTED AROMATIC
BICYCLIC COMPOUNDS, METHODS FOR
THEIR PREPARATION AND THEIR USE AS
PHARMACEUTICALS

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56 AND 1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

To comply with Applicants' duty of disclosure pursuant to 37 C.F.R. §§1.56 and 1.97, Applicants submit herewith on Form PTO/SB/08A a listing of documents known to Applicants. A copy of each of the listed documents is being submitted to comply with the provisions of 37 C.F.R. §§ 1.97-1.99.


The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present application.

The undersigned hereby states in accordance with 37 C.F.R. §1.97(e)(1) that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three 3) months prior to the filing of this Information Disclosure Statement. Therefore, Applicants believe that no fee is required. However, if a fee is required, Applicants authorize the USPTO to charge any fees to Deposit Account No. 08-1642, referencing Docket No. 38005-0194.


Applicants respectfully request that the listed documents be considered by the Examiner and made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Respectfully submitted,

Date: July 9, 2004


Patricia D. Granados
Attorney for Applicant
Registration No.: 33,683

Heller Ehrman White & McAuliffe LLP
1666 K Street, N.W., Suite 300
Washington, D.C. 20006-1228
Telephone: (202) 912-2000
Facsimile: (202) 912-2020
Customer No. 26633
dc146576v1



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/820,703
Filing Date	April 9, 2004
First Named Inventor	Lothar Schwink <i>et al.</i>
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	38005-0194

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	1.	US-4,405,644	09-20-1983	Kabbe <i>et al.</i>	
	2.	US-5,756,496	05-26-1998	Ham <i>et al.</i>	
	3.	US-6,310,107	10-30-2001	Kato <i>et al.</i>	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	4.	DD 29 28 584	01/29/1981	Bayer AG		
	5.	WO 01/82925	11/8/2001	Takeda Chemical Industries, Ltd.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	6.	US Patent Application Publication No. 2004/0077628 A1 by Ishihara <i>et al.</i> , "Melanin-Concentrating Hormone Antagonist", based on PCT/JP01/03614, assigned to Takeda Pharmaceuticals North America, Inc., published April 22, 2004.	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to filed (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2